bpc 157 dilarginine BPC-157 — Research Compound ·
Description
78.8% of the patients underwent surgical treatment, which included excision and primary closure with or without the use of skin grafts (85.1% of all procedures), the use of flaps (12.3%) and penile amputation ( n = 2)
also high levels of oxidative stress biomarkers and evidence of impaired methylation (high uridine)
GLOW (GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg) $125.00 Free shipping on orders over $200
10.1210/clinem/dgz324 50 SmitD
Both appear in research and practitioner protocols
